Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s Avastin demonstrates efficacy in phase III trial

Roche’s Avastin demonstrates efficacy in phase III trial

7th June 2010

Roche has reported data from a clinical trial of Avastin, which demonstrates the advantages it can deliver for ovarian cancer sufferers.

The phase III study was conducted among women with previously untreated advanced ovarian cancer and involved a combination of Avastin and chemotherapy, followed by a continuation of the Roche drug alone.

It was found that patients using this treatment regime had a 39 per cent better likelihood of progression-free survival than those using only chemotherapy.

Dr Hal Barron, head of global development and chief medical officer for Roche, stated that the company will now be looking to discuss the findings with regulatory authorities worldwide.

He added: “We are encouraged by these results as there have been few improvements in outcomes for women with this disease in the past decade.”

This data was presented at the American Society of Clinical Oncology’s annual meeting, an event which will also see Roche present new data on the follicular lymphoma treatment MabThera.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.